公开(公告)号：US20030086903A1

公开(公告)日：2003-05-08

申请号：US10001017

申请日：2001-11-02

Applicant: GenVec, Inc.

Inventor： Henrik S. Rasmussen ,  Karen W. Chu

IPC: A01N063/00

CPC classification number: A61K35/761 ,  A61K38/191 ,  C12N2710/10332 ,  C12N2710/10341 ,  A61K2300/00

Abstract: The present invention provides a method for reducing the size of a tumor in a human comprising (a) directly injecting into the tumor, via multiple injections to different points of the tumor, a dose of a pharmaceutical composition comprising (i) a pharmaceutically acceptable carrier and (ii) a replication-deficient adenoviral vector comprising a nucleic acid sequence encoding TNF-null operably linked to a promoter, wherein the dose comprises about 1null107 to about 4null1012 3 particle units (pu) of replication-deficient adenoviral vector, two or more times over a therapeutic period comprising up to 10 weeks, and (b) administering a dose of ionizing radiation over the duration of the therapeutic period, whereby the size of the tumor is reduced.

Abstract translation: 本发明提供了一种减少人体肿瘤大小的方法，包括（a）通过多次注射直接注射到肿瘤中，药物组合物的剂量包含（i）药学上可接受的载体 其包含可操作地连接到启动子的编码TNF-α的核酸序列的复制缺陷型腺病毒载体，其中所述剂量包含约1×10 7至约4×10 12 3个复制缺陷型腺病毒载体的颗粒单位（pu），两个或更多个 包括长达10周的治疗期，以及（b）在治疗期间内施用一定剂量的电离辐射，从而降低肿瘤的大小。

公开(公告)号：US20030086904A1

公开(公告)日：2003-05-08

申请号：US10151633

申请日：2002-05-17

Applicant: GenVec, Inc.

Inventor： Henrik S. Rasmussen ,  Karen W. Chu

IPC: A61K048/00 ,  C12N007/00 ,  C12N015/861

CPC classification number: A61K35/761 ,  A61K38/191 ,  C12N2710/10332 ,  C12N2710/10341 ,  A61K2300/00

Abstract: The invention provides a method for treating cancer in a human comprising administering to the human a dose of a pharmaceutical composition comprising (i) a pharmaceutically acceptable carrier and (ii) an adenoviral vector comprising a nucleic acid sequence encoding TNF-null operably linked to a promoter, wherein the dose comprises about 1null107 to about 4null1012 particle units (pu) of replication-deficient adenoviral vector, at least once in a therapeutic period comprising up to 10 weeks, whereby the cancer in human is treated. The invention further provides a method of treating a human for multiple tumors, wherein the method comprises contacting a first tumor with a dose of the pharmaceutical composition at least once in a therapeutic period comprising up to about 10 weeks, whereby the human is treated for the first tumor and one or more additional tumors.

Abstract translation: 本发明提供了一种治疗人类癌症的方法，包括向人施用剂量的药物组合物，其包含（i）药学上可接受的载体和（ii）腺病毒载体，其包含编码与α-α可操作地连接的TNF-α的核酸序列 启动子，其中所述剂量包含约1×10 7至约4×10 12个复制缺陷型腺病毒载体的颗粒单位（pu），在至多10周的治疗期内至少一次，由此治疗人类的癌症。 本发明进一步提供了治疗多种肿瘤的方法，其中所述方法包括使第一肿瘤与一定剂量的药物组合物在至多约10周的治疗期内至少接触一次，由此将该人治疗为 第一肿瘤和一个或多个另外的肿瘤。